A case of urinary incontinence by hydroxychloroquine in a geriatric patient
Identifieur interne : 000520 ( Istex/Curation ); précédent : 000519; suivant : 000521A case of urinary incontinence by hydroxychloroquine in a geriatric patient
Auteurs : C. Carnovale [Italie] ; V. Perrone [Italie] ; C. Borsadoli [Italie] ; A. Mambrini [Italie] ; A. Speziali [Italie] ; G. Froldi [Italie] ; S. Antoniazzi [Italie] ; L. Magistro [Italie] ; E. Clementi [Italie] ; S. Radice [Italie]Source :
- Journal of Clinical Pharmacy and Therapeutics [ 0269-4727 ] ; 2013-04.
English descriptors
- Teeft :
- Adverse drug reaction, Adverse effect, Adverse event, Antimalarial, Antinuclear antibodies, Azienda sanitaria locale, Blackwell publishing, Bladder, Chloroquine, Clinical pharmacology, Clinical pharmacy, Clinical sciences, Hydroxychloroquine, Incontinence, Ltration rate, Luigi sacco, Nacl transport, Nitric, Nitric oxide, Other antimalarial drugs, Pelvic echography, Pharmacol, Pharmacology, Pharmd, Probable cause, Renal, Renal function, Rheumatoid, Rheumatoid arthritis, University hospital, Urinary, Urinary bladder distension, Urinary incontinence, Vasopressin, Vasopressin secretion.
Abstract
What is known and Objective: Rheumatoid arthritis is an autoimmune disorder characterized by persistent synovitis and systemic inflammation. Genetic factors account for approximately 50% of cases of rheumatoid arthritis and environmental factors include smoking. Urinary incontinence may occur as a medication adverse effect. We present the first report of a case of hydroxychloroquine‐induced urinary incontinence in rheumatoid arthritis. Details of the case: A 71‐year‐old female with a history of rheumatoid arthritis developed urinary incontinence as an adverse drug reaction to hydroxychloroquine administered at therapeutic doses. Urinary incontinence remitted with drug withdrawal and reappeared on rechallenge. The Naranjo's algorithm indicated that hydroxychloroquine was a probable cause of this adverse drug reaction. The likely mechanism of this adverse drug is a direct action of the quinolone on the urinary system. What is new and conclusion: This is the first report of hydroxychloroquine‐induced urinary incontinence. The absence of previous reports suggest that the drug rarely causes this adverse effect. Methotrexate is most often used as first‐line treatment, and several other drugs are now available to act as Disease‐Modifying Antirheumatic Drugs (DMARDs). These drugs may be used alone or combined with methotrexate, most often to increase efficacy and reduce toxicity. The introduction of new biological agents, such as abatacept, rituximab, tocilizumab and inhibitors of tumour necrosis factor, has opened new therapeutic perspectives but are restricted by high costs and risk of infections. Thus, antimalarial drugs, especially the quinolones chloroquine (CQ) and hydroxychloroquine (HCQ), are still in use, and the latter is very efficacious. An advantage of HCQ is its low toxicity compared with other antimalarial drugs. Common side‐effects of HCQ and the other antimalarial drugs include gastrointestinal effects such as nausea and vomiting, as well as skin rashes and headache, whereas their most common and severe side‐effect is retinopathy. No case of urinopathy has been reported previously with HCQ.
Url:
DOI: 10.1111/jcpt.12024
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000520
Links to Exploration step
ISTEX:D29A91785C089D8077DB8AC1F4179A54DD338021Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A case of urinary incontinence by hydroxychloroquine in a geriatric patient</title><author><name sortKey="Carnovale, C" sort="Carnovale, C" uniqKey="Carnovale C" first="C." last="Carnovale">C. Carnovale</name><affiliation wicri:level="1"><mods:affiliation>Scientific Institute, IRCCS Eugenio Medea, Lecco, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Scientific Institute, IRCCS Eugenio Medea, Lecco</wicri:regionArea></affiliation></author><author><name sortKey="Perrone, V" sort="Perrone, V" uniqKey="Perrone V" first="V." last="Perrone">V. Perrone</name><affiliation wicri:level="1"><mods:affiliation>Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences, University Hospital ‘Luigi Sacco’, Università di Milano, Milan, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences, University Hospital ‘Luigi Sacco’, Università di Milano, Milan</wicri:regionArea></affiliation></author><author><name sortKey="Borsadoli, C" sort="Borsadoli, C" uniqKey="Borsadoli C" first="C." last="Borsadoli">C. Borsadoli</name><affiliation wicri:level="1"><mods:affiliation>Pharmaceutical Service, Azienda Sanitaria Locale di Mantova, Mantua, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Pharmaceutical Service, Azienda Sanitaria Locale di Mantova, Mantua</wicri:regionArea></affiliation></author><author><name sortKey="Mambrini, A" sort="Mambrini, A" uniqKey="Mambrini A" first="A." last="Mambrini">A. Mambrini</name><affiliation wicri:level="1"><mods:affiliation>Physician, Azienda Sanitaria Locale di Mantova, Mantua, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Physician, Azienda Sanitaria Locale di Mantova, Mantua</wicri:regionArea></affiliation></author><author><name sortKey="Speziali, A" sort="Speziali, A" uniqKey="Speziali A" first="A." last="Speziali">A. Speziali</name><affiliation wicri:level="1"><mods:affiliation>Pharmaceutical Service, Azienda Sanitaria Locale di Mantova, Mantua, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Pharmaceutical Service, Azienda Sanitaria Locale di Mantova, Mantua</wicri:regionArea></affiliation></author><author><name sortKey="Froldi, G" sort="Froldi, G" uniqKey="Froldi G" first="G." last="Froldi">G. Froldi</name><affiliation wicri:level="1"><mods:affiliation>Pharmaceutical Service, Azienda Sanitaria Locale di Mantova, Mantua, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Pharmaceutical Service, Azienda Sanitaria Locale di Mantova, Mantua</wicri:regionArea></affiliation></author><author><name sortKey="Antoniazzi, S" sort="Antoniazzi, S" uniqKey="Antoniazzi S" first="S." last="Antoniazzi">S. Antoniazzi</name><affiliation wicri:level="1"><mods:affiliation>Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences, University Hospital ‘Luigi Sacco’, Università di Milano, Milan, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences, University Hospital ‘Luigi Sacco’, Università di Milano, Milan</wicri:regionArea></affiliation></author><author><name sortKey="Magistro, L" sort="Magistro, L" uniqKey="Magistro L" first="L." last="Magistro">L. Magistro</name><affiliation wicri:level="1"><mods:affiliation>Department of Pharmacology “E. Trabucchi”, Postgraduate School of Clinical Pharmacology, Università di Milano, Milan, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Pharmacology “E. Trabucchi”, Postgraduate School of Clinical Pharmacology, Università di Milano, Milan</wicri:regionArea></affiliation></author><author><name sortKey="Clementi, E" sort="Clementi, E" uniqKey="Clementi E" first="E." last="Clementi">E. Clementi</name><affiliation wicri:level="1"><mods:affiliation>Scientific Institute, IRCCS Eugenio Medea, Lecco, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Scientific Institute, IRCCS Eugenio Medea, Lecco</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences, University Hospital ‘Luigi Sacco’, Università di Milano, Milan, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences, University Hospital ‘Luigi Sacco’, Università di Milano, Milan</wicri:regionArea></affiliation></author><author><name sortKey="Radice, S" sort="Radice, S" uniqKey="Radice S" first="S." last="Radice">S. Radice</name><affiliation wicri:level="1"><mods:affiliation>Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences, University Hospital ‘Luigi Sacco’, Università di Milano, Milan, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences, University Hospital ‘Luigi Sacco’, Università di Milano, Milan</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>E-mail: sonia.radice@unimi.it</mods:affiliation><country wicri:rule="url">Italie</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D29A91785C089D8077DB8AC1F4179A54DD338021</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1111/jcpt.12024</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-8TC4Q054-2/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000520</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000520</idno><idno type="wicri:Area/Istex/Curation">000520</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">A case of urinary incontinence by hydroxychloroquine in a geriatric patient</title><author><name sortKey="Carnovale, C" sort="Carnovale, C" uniqKey="Carnovale C" first="C." last="Carnovale">C. Carnovale</name><affiliation wicri:level="1"><mods:affiliation>Scientific Institute, IRCCS Eugenio Medea, Lecco, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Scientific Institute, IRCCS Eugenio Medea, Lecco</wicri:regionArea></affiliation></author><author><name sortKey="Perrone, V" sort="Perrone, V" uniqKey="Perrone V" first="V." last="Perrone">V. Perrone</name><affiliation wicri:level="1"><mods:affiliation>Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences, University Hospital ‘Luigi Sacco’, Università di Milano, Milan, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences, University Hospital ‘Luigi Sacco’, Università di Milano, Milan</wicri:regionArea></affiliation></author><author><name sortKey="Borsadoli, C" sort="Borsadoli, C" uniqKey="Borsadoli C" first="C." last="Borsadoli">C. Borsadoli</name><affiliation wicri:level="1"><mods:affiliation>Pharmaceutical Service, Azienda Sanitaria Locale di Mantova, Mantua, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Pharmaceutical Service, Azienda Sanitaria Locale di Mantova, Mantua</wicri:regionArea></affiliation></author><author><name sortKey="Mambrini, A" sort="Mambrini, A" uniqKey="Mambrini A" first="A." last="Mambrini">A. Mambrini</name><affiliation wicri:level="1"><mods:affiliation>Physician, Azienda Sanitaria Locale di Mantova, Mantua, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Physician, Azienda Sanitaria Locale di Mantova, Mantua</wicri:regionArea></affiliation></author><author><name sortKey="Speziali, A" sort="Speziali, A" uniqKey="Speziali A" first="A." last="Speziali">A. Speziali</name><affiliation wicri:level="1"><mods:affiliation>Pharmaceutical Service, Azienda Sanitaria Locale di Mantova, Mantua, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Pharmaceutical Service, Azienda Sanitaria Locale di Mantova, Mantua</wicri:regionArea></affiliation></author><author><name sortKey="Froldi, G" sort="Froldi, G" uniqKey="Froldi G" first="G." last="Froldi">G. Froldi</name><affiliation wicri:level="1"><mods:affiliation>Pharmaceutical Service, Azienda Sanitaria Locale di Mantova, Mantua, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Pharmaceutical Service, Azienda Sanitaria Locale di Mantova, Mantua</wicri:regionArea></affiliation></author><author><name sortKey="Antoniazzi, S" sort="Antoniazzi, S" uniqKey="Antoniazzi S" first="S." last="Antoniazzi">S. Antoniazzi</name><affiliation wicri:level="1"><mods:affiliation>Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences, University Hospital ‘Luigi Sacco’, Università di Milano, Milan, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences, University Hospital ‘Luigi Sacco’, Università di Milano, Milan</wicri:regionArea></affiliation></author><author><name sortKey="Magistro, L" sort="Magistro, L" uniqKey="Magistro L" first="L." last="Magistro">L. Magistro</name><affiliation wicri:level="1"><mods:affiliation>Department of Pharmacology “E. Trabucchi”, Postgraduate School of Clinical Pharmacology, Università di Milano, Milan, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Pharmacology “E. Trabucchi”, Postgraduate School of Clinical Pharmacology, Università di Milano, Milan</wicri:regionArea></affiliation></author><author><name sortKey="Clementi, E" sort="Clementi, E" uniqKey="Clementi E" first="E." last="Clementi">E. Clementi</name><affiliation wicri:level="1"><mods:affiliation>Scientific Institute, IRCCS Eugenio Medea, Lecco, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Scientific Institute, IRCCS Eugenio Medea, Lecco</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences, University Hospital ‘Luigi Sacco’, Università di Milano, Milan, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences, University Hospital ‘Luigi Sacco’, Università di Milano, Milan</wicri:regionArea></affiliation></author><author><name sortKey="Radice, S" sort="Radice, S" uniqKey="Radice S" first="S." last="Radice">S. Radice</name><affiliation wicri:level="1"><mods:affiliation>Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences, University Hospital ‘Luigi Sacco’, Università di Milano, Milan, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences, University Hospital ‘Luigi Sacco’, Università di Milano, Milan</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>E-mail: sonia.radice@unimi.it</mods:affiliation><country wicri:rule="url">Italie</country></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Clinical Pharmacy and Therapeutics</title><title level="j" type="alt">JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS</title><idno type="ISSN">0269-4727</idno><idno type="eISSN">1365-2710</idno><imprint><biblScope unit="vol">38</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="169">169</biblScope><biblScope unit="page" to="171">171</biblScope><biblScope unit="page-count">3</biblScope><date type="published" when="2013-04">2013-04</date></imprint><idno type="ISSN">0269-4727</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0269-4727</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Adverse drug reaction</term><term>Adverse effect</term><term>Adverse event</term><term>Antimalarial</term><term>Antinuclear antibodies</term><term>Azienda sanitaria locale</term><term>Blackwell publishing</term><term>Bladder</term><term>Chloroquine</term><term>Clinical pharmacology</term><term>Clinical pharmacy</term><term>Clinical sciences</term><term>Hydroxychloroquine</term><term>Incontinence</term><term>Ltration rate</term><term>Luigi sacco</term><term>Nacl transport</term><term>Nitric</term><term>Nitric oxide</term><term>Other antimalarial drugs</term><term>Pelvic echography</term><term>Pharmacol</term><term>Pharmacology</term><term>Pharmd</term><term>Probable cause</term><term>Renal</term><term>Renal function</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>University hospital</term><term>Urinary</term><term>Urinary bladder distension</term><term>Urinary incontinence</term><term>Vasopressin</term><term>Vasopressin secretion</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">What is known and Objective: Rheumatoid arthritis is an autoimmune disorder characterized by persistent synovitis and systemic inflammation. Genetic factors account for approximately 50% of cases of rheumatoid arthritis and environmental factors include smoking. Urinary incontinence may occur as a medication adverse effect. We present the first report of a case of hydroxychloroquine‐induced urinary incontinence in rheumatoid arthritis. Details of the case: A 71‐year‐old female with a history of rheumatoid arthritis developed urinary incontinence as an adverse drug reaction to hydroxychloroquine administered at therapeutic doses. Urinary incontinence remitted with drug withdrawal and reappeared on rechallenge. The Naranjo's algorithm indicated that hydroxychloroquine was a probable cause of this adverse drug reaction. The likely mechanism of this adverse drug is a direct action of the quinolone on the urinary system. What is new and conclusion: This is the first report of hydroxychloroquine‐induced urinary incontinence. The absence of previous reports suggest that the drug rarely causes this adverse effect. Methotrexate is most often used as first‐line treatment, and several other drugs are now available to act as Disease‐Modifying Antirheumatic Drugs (DMARDs). These drugs may be used alone or combined with methotrexate, most often to increase efficacy and reduce toxicity. The introduction of new biological agents, such as abatacept, rituximab, tocilizumab and inhibitors of tumour necrosis factor, has opened new therapeutic perspectives but are restricted by high costs and risk of infections. Thus, antimalarial drugs, especially the quinolones chloroquine (CQ) and hydroxychloroquine (HCQ), are still in use, and the latter is very efficacious. An advantage of HCQ is its low toxicity compared with other antimalarial drugs. Common side‐effects of HCQ and the other antimalarial drugs include gastrointestinal effects such as nausea and vomiting, as well as skin rashes and headache, whereas their most common and severe side‐effect is retinopathy. No case of urinopathy has been reported previously with HCQ.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000520 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000520 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:D29A91785C089D8077DB8AC1F4179A54DD338021
|texte= A case of urinary incontinence by hydroxychloroquine in a geriatric patient
}}
| This area was generated with Dilib version V0.6.34. |  |